Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 86Kidney Neoplasms 25Neoplasms 24Breast Neoplasms 18Gastrointestinal Stromal Tumors 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Pancreatic Neoplasms 6Lung Neoplasms 6Colorectal Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Solid Tumors 5Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Neuroendocrine Tumors 5Melanoma 5Glioblastoma 5Carcinoma 5Sarcoma 4Liver Neoplasms 4Esophageal Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Adenoma, Islet Cell 4Thyroid Cancer, Papillary 3

Interventions

pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vorinostat 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Malignant Solid Tumour × Sunitinib × Clear all
NCT01286896 2025-07-10

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

The Netherlands Cancer Institute

Phase 1 Completed
43 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡